About ABAGEN®

Abagen® is a pioneering anti-inflammatory peptide derived from blacklip abalone (Haliotis rubra), a marine species native to Australia’s coastal waters. Developed through a patented process (WO 2017/124149) in collaboration with the Commonwealth Scientific and Industrial Research Organisation (CSIRO), Abagen is brought to you by Southern Ocean Biotech, based in Portland, Victoria.

Supported by peer-reviewed studies (Suleria et al., 2017), this peptide taps into the natural bioactive potential of abalone, offering a scientifically validated approach to combating inflammation.

Key Features of Abagen®

  • Anti-Inflammatory Potency:
    Demonstrates significant reduction in nitric oxide production (up to 79%) and IL-6 levels, key markers of inflammation, as evidenced in preclinical studies (Patent WO 2017/124149; Suleria et al., 2017).

  • Natural Source:
    Derived from blacklip abalone, providing a marine-based, protein-rich peptide with inherent anti-inflammatory properties.

  • Protein Enrichment:
    Fractionated to concentrate protein components, enhancing its efficacy for conditions like rheumatoid arthritis (Patent WO 2017/124149).

  • Scientific Foundation:
    Supported by extensive research, including in vitro macrophage studies and in vivo arthritis models, ensuring credibility for medical applications (Suleria et al., 2017; Patent WO 2017/124149).

Our Mission

At Southern Ocean Biotech, our mission is to empower doctors and scientists with a novel, evidence-based tool to address chronic inflammatory conditions. By leveraging the natural anti-inflammatory properties of blacklip abalone, we aim to advance medical research and improve patient outcomes through innovative marine-derived therapies.

The Development Team

Abagen was created through a partnership between Southern Ocean Biotech and CSIRO, with key contributions from inventor Dr. Simone Osborne.

Be the First to Discover Abagen®

Subscribe for exclusive updates!
Get early access to information about Abagen®